Keywords: skyepharma, issues, full-year, profit, warning, unsteady, revenues
SkyePharma issues full-year profit warning; unsteady revenues still to blame
Article | 29 September 2003
UK-based drug delivery specialist SkyePharma says that full-year 2003 revenues could now come in as low as L85 million ($141.9 million), depending ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
